Alprazolam and diazepam: addiction potential
- PMID: 2051498
- DOI: 10.1016/0740-5472(91)90026-7
Alprazolam and diazepam: addiction potential
Abstract
Alprazolam and diazepam, the two most prescribed benzodiazepine anxiolytics in the United States, have potential for addictive use. The Drug Abuse Warning Network (DAWN) indicates they are the most mentioned benzodiazepines, and the National Household Survey indicates significant abuse of tranquilizers. Both drugs are rapidly absorbed and enter the brain tissue rapidly, leading to reinforcement. Alprazolam has a shorter half-life, which may lead to more withdrawal symptoms than diazepam. In experimental conditions, they are among the most reinforcing benzodiazepines. Each causes a withdrawal syndrome, but alprazolam withdrawal may be more severe and may occur after a shorter period of use. Adverse effects from their use are said to be rare, yet subtle negative consequences may be seen with some regularity. Alprazolam deserves special caution because of its relative newness, great popularity, reinforcing capabilities, relatively severe withdrawal syndrome, and reports of addiction and negative consequences of use.
Similar articles
-
Controlled discontinuation of benzodiazepine treatment for patients with panic disorder.Am J Psychiatry. 1991 Apr;148(4):517-23. doi: 10.1176/ajp.148.4.517. Am J Psychiatry. 1991. PMID: 2006699 Clinical Trial.
-
Withdrawal and detoxification from benzodiazepine dependence: a potential role for clonazepam.J Clin Psychiatry. 1987 Oct;48 Suppl:43-9. J Clin Psychiatry. 1987. PMID: 2889723 Review.
-
The seeking and liking potentials of alprazolam.Am J Psychiatry. 1988 Jan;145(1):128. doi: 10.1176/ajp.145.1.128a. Am J Psychiatry. 1988. PMID: 3337279 No abstract available.
-
Benzodiazepine withdrawal.Am J Psychiatry. 1991 Nov;148(11):1621. doi: 10.1176/ajp.148.11.1621b. Am J Psychiatry. 1991. PMID: 1928509 No abstract available.
-
Short-acting versus long-acting benzodiazepines: discontinuation effects in panic disorders.J Psychiatr Res. 1990;24 Suppl 2:65-72. doi: 10.1016/0022-3956(90)90037-q. J Psychiatr Res. 1990. PMID: 1980701 Review.
Cited by
-
A Pharmacological Update of Triazole Derivative: A Review.Curr Top Med Chem. 2024;24(23):2033-2049. doi: 10.2174/0115680266308359240708094001. Curr Top Med Chem. 2024. PMID: 39069706 Review.
-
Antidepressant- and Anxiolytic-like Effects in Mice of Alkaloids from Aerial Parts of Argemone platyceras Link & Otto.Pharmaceuticals (Basel). 2025 Jan 3;18(1):49. doi: 10.3390/ph18010049. Pharmaceuticals (Basel). 2025. PMID: 39861112 Free PMC article.
-
A real-world pharmacovigilance study of FDA adverse event reporting system events for diazepam.Front Pharmacol. 2024 Jan 24;15:1278442. doi: 10.3389/fphar.2024.1278442. eCollection 2024. Front Pharmacol. 2024. PMID: 38327980 Free PMC article.
-
Preferences for ethanol and diazepam in anxious individuals: an evaluation of the self-medication hypothesis.Psychopharmacology (Berl). 1995 Sep;121(1):91-103. doi: 10.1007/BF02245595. Psychopharmacology (Berl). 1995. PMID: 8539345 Clinical Trial.
-
Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation.PLoS One. 2016 Sep 7;11(9):e0162452. doi: 10.1371/journal.pone.0162452. eCollection 2016. PLoS One. 2016. PMID: 27603791 Free PMC article.